Collections

  • Collection |

    Autoimmunity is an underlying cause of many diseases. This collection of Research, Reviews and News articles from several Nature journals covers the latest advances in genetic and epigenetic research into autoimmunity and autoimmune diseases.

    Image: Susanne Harris/Springer Nature Limited
  • Collection |

    Cancer immunotherapy, which encompasses a variety of approaches that mobilise the immune system to seek out and kill cancer cells, is showing substantial potential to transform the treatment of cancer. Articles in this collection highlight the progress being made with several of the most promising immunotherapy approaches and discuss key issues for maximizing their benefits, such as how immunotherapies may be rationally combined with each other or with traditional anticancer drugs.

  • Series |

    A special series of articles discussing the opportunities and challenges for cancer immunotherapy.

  • Focus |

    Launched a decade ago, the US Food and Drug Administration's Critical Path Initiative has helped catalyse the formation of many consortia focused on drug development challenges. In this Focus, representatives from some of the major stakeholder groups and consortia describe their roles, summarize progress so far and provide their perspectives on the opportunities, challenges and lessons learned for biomedical consortia in general.

  • Collection |

    To mark the tenth anniversary of Nature Reviews Drug Discovery, this collection brings together data on key indicators for the field over the past decade, as well as a selection of some of the most highly cited and downloaded articles published in the journal from each of the last ten years.

  • Collection |

    Many of the thousands of rare diseases lack effective treatments. However, economic and regulatory incentives, as well as advances in our understanding of disease aetiology, have encouraged increased investment in the development of drugs for rare diseases — orphan drugs. This special collection from Nature Reviews Drug Discoveryincludes articles that discuss the impact of orphan drug legislation in the United States and Europe, and that review recent therapeutic progress for two groups of rare diseases: neuromuscular disorders and myeloproliferative neoplasias.

  • Collection |

    The rapid growth in the prevalence of type 2 diabetes is increasing the need for effective therapeutic interventions. However, although multiple classes of diabetes drugs are available, achieving long-term control of blood sugar is often a major challenge, in part owing to treatment-limiting adverse effects. With these challenges in mind, this special collection of articles from Nature Reviews Drug Discoveryfocuses on emerging therapeutic approaches and targets for type 2 diabetes.

  • Focus |

    To highlight the problem of resistance to antimicrobials, Nature Reviews Microbiology presents a set of specially commissioned articles that focus on key issues in the field, including the role of antibiotic resistance in nature, how the spread of antimicrobial resistance could be limited and the pharmaceutical strategies that are used to overcome resistance to various classes of antimicrobials. The Focus issue is accompanied by a joint Web Focus with Nature Reviews Drug Discovery.

  • Focus |

    Apoptosis, the major form of controlled cell death, has a key role in the pathogenesis of diseases including cancer, inflammation and neurodegenerative disorders. The past decade has witnessed tremendous progress in understanding of the molecular mechanisms of apoptosis regulation, which has revealed a number of highly promising therapeutic targets, particularly for anticancer strategies. This focus provides a cutting-edge overview of the science and business of targeting apoptosis.

  • Focus |

    Unrelieved pain associated with conditions such as arthritis, diabetes, cancer and serious injury represents a major unmet medical need. With the aim of highlighting approaches to tackling the challenges in this field, this special collection integrates articles that discuss strategies to drive forward analgesic drug development with those that explore new targets for pain therapeutics.